-
Publication Venue For
-
Personalized Cancer Follow-Up Care Pathways: A Delphi Consensus of Research Priorities..
112:1183-1189.
2020
-
Response to Strassels and Durham..
112:1280.
2020
-
Racial differences in population attributable risk for epithelial ovarian cancer in the OCWAA Consortium.
2020
-
The Role of Neoadjuvant Chemotherapy in Patients With Resectable Malignant Pleural Mesothelioma-An Institutional and National Analysis..
112:1118-1127.
2020
-
Validity and Reliability of the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events..
112:1143-1152.
2020
-
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design..
112:1021-1029.
2020
-
Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy.
2020
-
Borderline Estrogen Receptor-Positive Breast Cancers in Black and White Women..
112:728-736.
2020
-
Concurrent Opioid and Benzodiazepine Prescriptions Among Older Women Diagnosed With Breast Cancer..
112:765-768.
2020
-
Radiation Dose and Volume to the Pancreas and Subsequent Risk of Diabetes Mellitus: A Report from the Childhood Cancer Survivor Study..
112:525-532.
2020
-
Traditional Cardiovascular Risk Factors and Individual Prediction of Cardiovascular Events in Childhood Cancer Survivors..
112:256-265.
2020
-
Response to Habel and Buist..
112:216-217.
2020
-
Uncovering the Role of RNA-Binding Protein hnRNP K in B-Cell Lymphomas..
112:95-106.
2020
-
Measuring Aging and Identifying Aging Phenotypes in Cancer Survivors..
111:1245-1254.
2019
-
Cost-Effectiveness of Colonoscopy-Based Colorectal Cancer Screening in Childhood Cancer Survivors..
111:1161-1169.
2019
-
Cancer Outcomes in DCIS Patients Without Locoregional Treatment..
111:952-960.
2019
-
Childhood Leukemia, Late Effects, and a Person-centric Model of Follow-up..
111:880-881.
2019
-
Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance)..
111:170-179.
2019
-
Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage..
111:60-68.
2019
-
Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer..
110:1360-1369.
2018
-
Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients..
110:1084-1093.
2018
-
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms..
110:1067-1074.
2018
-
Defining Value of Cancer Therapeutics-A Health System Perspective..
110:699-703.
2018
-
Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project..
110:638-648.
2018
-
Chronic Health Conditions and Neurocognitive Function in Aging Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study..
110:411-419.
2018
-
Prostate Cancer Patient Characteristics Associated With a Strong Preference to Preserve Sexual Function and Receipt of Active Surveillance..
110:420-425.
2018
-
The Future of Radiobiology..
110:329-340.
2018
-
Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study..
110.
2018
-
Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer..
109.
2017
-
Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research..
109.
2017
-
Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies..
109.
2017
-
Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies..
109.
2017
-
Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer..
109.
2017
-
Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer..
109.
2017
-
What Can Molecular Diagnostics Add to Locoregional Treatment Recommendations for DCIS?.
109.
2017
-
Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans..
108.
2016
-
Chronic Conditions and Utility-Based Health-Related Quality of Life in Adult Childhood Cancer Survivors..
108.
2016
-
Financial Toxicity of Cancer Care: It's Time to Intervene..
108.
2016
-
Outcomes of Active Surveillance for Ductal Carcinoma in Situ: A Computational Risk Analysis..
108.
2016
-
The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative..
108.
2016
-
The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP)..
107:djv261.
2015
-
Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ..
107:djv263.
2015
-
Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer..
107.
2015
-
Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance)..
107.
2015
-
Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases..
107.
2015
-
On the quantitative assessment of predictive biomarkers..
107.
2015
-
Supplemental security income and social security disability insurance coverage among long-term childhood cancer survivors..
107:djv057.
2015
-
Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise..
107.
2015
-
Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthood..
107.
2015
-
Primary tumor location as a prognostic factor in metastatic colorectal cancer..
107.
2015
-
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer..
107:345.
2015
-
Germline mutations in shelterin complex genes are associated with familial glioma..
107:384.
2015
-
Opportunities-and hard work-ahead..
107:398.
2015
-
Combining targeted agents with modern radiotherapy in soft tissue sarcomas..
106.
2014
-
Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)..
106.
2014
-
25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance)..
106.
2014
-
ABCA transporter gene expression and poor outcome in epithelial ovarian cancer..
106.
2014
-
Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials..
106.
2014
-
Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials..
106.
2014
-
Recommended patient-reported core set of symptoms to measure in head and neck cancer treatment trials..
106.
2014
-
Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials..
106.
2014
-
Treatment trends, risk of lymph node metastasis, and outcomes for localized esophageal cancer..
106.
2014
-
Impact of patient navigation on timely cancer care: the Patient Navigation Research Program..
106:dju115.
2014
-
Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis..
106.
2014
-
Multiple myeloma in the very old: an IASIA conference report..
106.
2014
-
Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium..
106:djt431.
2014
-
Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma..
106.
2014
-
Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis..
106.
2014
-
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial..
105:1789-1798.
2013
-
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy..
105:1729-1737.
2013
-
Recommendations for high-priority research on cancer-related fatigue in children and adults..
105:1432-1440.
2013
-
Inhibiting the inhibitor: targeting vascular endothelial protein tyrosine phosphatase to promote tumor vascular maturation..
105:1163-1165.
2013
-
Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects..
105:929-936.
2013
-
Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations..
105:733-742.
2013
-
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy..
105:499-503.
2013
-
Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803..
104:1702-1711.
2012
-
Biological, clinical, and psychosocial correlates at the interface of cancer and aging research..
104:581-589.
2012
-
Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival..
103:1851-1858.
2011
-
Molecular characterization of the tumor-suppressive function of nischarin in breast cancer..
103:1513-1528.
2011
-
Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803..
103:1540-1551.
2011
-
Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk..
103:1342-1346.
2011
-
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1..
103:1190-1204.
2011
-
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation..
102:1698-1705.
2010
-
Evidence that Gsta4 modifies susceptibility to skin tumor development in mice and humans..
102:1663-1675.
2010
-
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer..
102:1496-1512.
2010
-
Functional assessment and the cancer survivor: something old, something new..
102:1450-1451.
2010
-
Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study..
102:1272-1283.
2010
-
Testicular cancer survivorship: research strategies and recommendations..
102:1114-1130.
2010
-
Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer..
102:942-949.
2010
-
Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism..
102:932-941.
2010
-
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women..
102:325-339.
2010
-
Association of a cancer diagnosis with vulnerability and frailty in older Medicare beneficiaries..
101:1206-1215.
2009
-
Impact of cancer on health-related quality of life of older Americans..
101:860-868.
2009
-
Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding..
101:543-545.
2009
-
Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials..
101:256-266.
2009
-
The influence of statin medications on prostate-specific antigen levels..
100:1511-1518.
2008
-
Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens..
100:681-682.
2008
-
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab..
99:1232-1239.
2007
-
Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium..
99:777-789.
2007
-
Response rate as an endpoint in clinical trials..
99:98-99.
2007
-
Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects..
99:53-63.
2007
-
Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344)..
98:1335-1338.
2006
-
Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model..
98:1238-1247.
2006
-
Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs..
98:1118-1128.
2006
-
Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation..
98:855-868.
2006
-
Lung cancer screening, overdiagnosis bias, and reevaluation of the Mayo Lung Project..
98:724-725.
2006
-
Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers..
98:335-344.
2006
-
Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS)..
98:92-100.
2006
-
In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis..
97:1822-1831.
2005
-
Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants..
97:1080-1083.
2005
-
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab..
97:981-989.
2005
-
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)..
97:94-102.
2005
-
Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial..
96:1083-1094.
2004
-
Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure..
96:509-515.
2004
-
Selection bias, phase II trials, and the FDA accelerated approval process..
95:1351-1352.
2003
-
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy..
95:1376-1383.
2003
-
RESPONSE: re: initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models.
92:1445-1446.
2000
-
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers..
108.
2016